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Abstract
Objective
To describe antiretroviral therapy (ART) adherence and associated factors for a large HIV-
infected pediatric cohort followed by sites of the East Africa International Epidemiologic
Databases to Evaluate AIDS (IeDEA) consortium.
Methods
This study utilized prospectively collected clinical data from HIV-infected children less than
13 years of age who initiated ART within 4 clinical care programs (with 26 clinical sites) in
Kenya, Uganda, and Tanzania and were followed for up to 6 years. Programs used one of 3
adherence measures, including 7-day quantitative recall, 7-day categorical recall, and clini-
cian pill assessments. We fit a hierarchical, three-level, logistic-regression model to exam-
ine adherence, with observations nested within patient, and patients within the 26 sites
providing pediatric HIV data to this analysis.
Results
In East Africa, 3,304 children, 52.0% male, were enrolled in care and were subsequently
observed for a median of 92 weeks (inter-quartile range [IQR] 50.3–145.0 weeks). Median
age at ART initiation was 5.5 years ([IQR] 3.0–8.5 years). “Good” adherence, as reported by
each clinic’s measures, was extremely high, remaining on average above 90% throughout
all years of follow-up. Longer time on ART was associated with higher adherence (adjusted
Odds Ratio–aOR–per log-transformed week on ART: 1.095, 95% Confidence Interval–CI–
[1.052–1.150].) Patients enrolled in higher-volume programs exhibited higher rates of clini-
cian-assessed adherence (aOR per log-500 patients: 1.174, 95% CI [1.108–1.245]).
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Significant site-level variability in reported adherence was observed (0.28), with even higher
variability among patients (0.71). In a sub-analysis, being an orphan at the start of ART was
strongly associated with lower ART adherence rates (aOR: 0.919, 95% CI [0.864–0.976]).
Conclusions
Self-reported adherence remained high over a median of 1.8 years in HIV care, but varied
according to patient-level and site-level factors. Consistent adherence monitoring with vali-
dated measures and attention to vulnerable groups is recommended.
Introduction
The advent of antiretroviral therapy (ART) has transformed HIV infection from a rapidly ter-
minal illness into a chronic disease. ART suppresses HIV replication, reduces HIV morbidity
and mortality, and improves the lives of HIV-infected children [1–5] but successful long-term
treatment depends on adherence to ART regimens. Patients who do not maintain adequate
adherence to ART are at greater risk of viral resistance to the available antiretroviral drugs,[6–
10] of immunologic decline resulting in opportunistic infections[11] and HIV disease progres-
sion,[12–17] and of transmitting resistant HIV at sexual debut.[18] Good ART adherence, typ-
ically defined as 90% or greater of doses taken as prescribed, decreases children’s HIV-related
morbidity and mortality.[13, 19–21]
Over 90% of the world’s 3.4 million HIV-infected children live in the resource-limited set-
tings of sub-Sahara Africa.[22, 23] While children’s access to ART in these settings is rapidly
expanding, many patients still do not have access to second-line ART regimens and even fewer
have access to third-line regimens.[24] Guidelines for pediatric HIV treatment recommend
immediate ART initiation for HIV-infected infants, which should significantly reduce mortal-
ity among young children, but older children are expected to continue to have growing AIDS
mortality.[25] Non-adherence and subsequent viral resistance could eliminate children’s lim-
ited treatment options.
Data from sub-Saharan Africa are still accumulating, but current estimates of pediatric
ART adherence in resource-limited settings have ranged widely, with reports that 24.6% to
100% of their children have perfect adherence.[26–42] Despite this wide range, the majority of
studies from resource-limited settings report good adherence among HIV-infected children;
76% of the studies included in a systematic review of pediatric ART adherence in low- and
middle-income countries reported greater than 75% ART adherence, but few had been treat-
ing children for more than 3 years.[26] Most of these studies used caregiver reports of adher-
ence, but self-reported adherence among older children or adolescents may yield reports of
more non-adherence. In a study from Zimbabwe, 39% of adolescents reported suboptimal
adherence, but significantly fewer reported suboptimal adherence if guardians were present in
the room [37]. Other studies in sub-Saharan Africa have been able to prospectively measure
adherence with more intensive and typically more valid methods, but these evaluations usually
involve smaller numbers of children and collect adherence data prospectively for research.
Such methods include home-based pill counts [35, 40], clinic-based pill counts [39], medica-
tion event monitoring systems (MEMS1) [36, 42, 43], plasma drug concentrations [38] and
hair drug concentrations [41]. Few treatment programs in sub-Saharan Africa have been able
to report on children’s adherence over the long-term or within large cohorts. In addition,
these studies primarily focus on individual-level factors associated with adherence, without
consideration of site- or facility-level contributions.
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The objective of this study was to describe pediatric ART adherence for a large clinical
cohort of HIV-infected children in East Africa. Data from the East Africa International Epide-
miologic Databases to Evaluate AIDS (IeDEA) consortium were used to estimate ART adher-
ence and to investigate both patient-level and site-level factors associated with ART non-
adherence.
Methods
Study design
This study used prospectively collected, de-identified data from the computerized medical rec-
ords of HIV-infected, pediatric patients treated in 26 sites belonging to 4 HIV care and treat-
ment programs affiliated with the East Africa IeDEA consortium in Kenya, Uganda, and
Tanzania until December 31, 2010. We sought to describe physician-assessed pediatric adher-
ence, whether self-reported, proxy-reported, or assessed by the clinician via other methods,
and associated patient or site-level factors. Each participating pediatric HIV clinic formally
agreed to be included in the IeDEA collaboration, with local Institutional Review Board
approvals.
Study sites
Established in 2006, IeDEA is a global data consortium funded by the United States National
Institutes of Health to develop 7 regional data centers to compile global data to address
research questions about HIV/AIDS treatment and care that cannot be answered with individ-
ual cohorts (see www.iedea.org).[44] The East Africa IeDEA regional Consortium involves
clinics providing HIV care and treatment in Kenya, Uganda, and Tanzania. Four of these clini-
cal care programs provide care for children and adolescents (at 26 clinc sites) and are included
in this analysis. These four programs are: 1) Academic Model Providing Access to Healthcare
(AMPATH) clinical care system in western Kenya (AMPATH consists of 25 clinics and 40 sat-
ellite clinics; 17 of the main clinic sites provide pediatric care)[45], 2) Family AIDS Care and
Educational Services (FACES) in Kisumu, Kenya (FACES included 4 clinic sites, Family
Health Options Kenya–FHOK, Lumumba, Pandpieri, and Tuungane)[46]; 3) the Mother-to-
Child Transmission-Plus (MTCT-Plus) program (with 3 clinic sites, the Nyanza Provincial
General Hospital in Kisumu, Kenya, the Makerere University–Johns Hopkins University
Research Collaboration (MUJHU) in Kampala, Uganda and the St. Francis Hospital–Nsambya
in Kampala, Uganda)[47]; and 4) the Tanzania Ministry of Health Community Development,
Gender, Elderly and Children (MoHCDGEC) (with 2 clinic sites, Morogoro Regional Hospital
in Morogoro, Tanzania; and the Tumbi Special Hospital in Kibaha, Tanzania). For the purpose
of this analysis, AMPATH, FACES, MTCT-plus, and MoHCDGEC are refered to as programs,
where as the individuals clinics within reach program are referred to as sites, In addition, any
satellite clinic data from the AMPATH program were incorporated into their main “parent”
clinic, which provides pediatric medical supervision.
Over the course of 10 years of collaboration in IeDEA, the programs have standardized pro-
tocols for data collection related to pediatric HIV care. However, the East Africa IeDEA sites
each followed their own, local clinical protocols and procedures during the time period of the
analysis and the systems may have implemented the protocols differently or to varying degrees.
HIV-infected children were typically seen at least every three months. During the time period
of this study, children’s CD4 counts were supposed to be measured once or twice a year for
immunologic monitoring. Routine viral load monitoring was not performed at any of the sites
at the time of these analyses. All sites had access to first-line antiretroviral therapy (ART) for
children.
Pediatric ART adherence in East Africa
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Ethical considerations
This analysis was approved as part of the projects of East African IeDEA by the Indiana Uni-
versity institutional research ethics board (IRB) as well as the local, and where appropriate,
national regulatory bodies affiliated with the participating sites and regional data centers. As
the analysis utilizes de-identified data collected within routine care, the local institutional
research ethics boards or committees did not require written informed consent for patient-
level data to be utilized in this analysis.
Study population
Eligible patients included HIV-infected children who had at least one medical visit at any of
the pediatric HIV care sites of the East Africa IeDEA consortium between January 2002 and
January 2009; had initiated ART; and had at least one ART adherence measure recorded in the
electronic medical record database prior to 13 years of age. In most of these sites, children
above 13 receive care within the adult clinics. Thus, the study population was limited to those
still considered “children” at the time of the adherence assessment across the various care pro-
grams. Child anthropometric data were categorized according to the WHO Growth Standards
[48] and orphanhood was defined using the standard definition of having a mother dead, a
father dead, or both [49].
Data collection and adherence measures
A computerized clinical data collection system with a common set of variables for all sites was
established for the participating IeDEA HIV care programs. Both site-level and patient-level
data were extracted from the electronic medical record for this study and validated following
established standard operating procedures within the East Africa IeDEA collaboration. The
mechanisms for receiving and combining data from individual sites, including training on
data collection; processing and cleaning; verifying data quality; and implementing methods for
analyzing cohort data are all standardized.
The clinical sites recorded adherence data using one of 3 different adherence measures: a
7-day quantitative recall, a 7-day categorical recall of any missed pills, or a clinician pill assess-
ment. Whether the recall items were asked of the child or the caregiver was not specified for
the data within the electronic database. Clinical protocols at the sites using the recall methods
generally direct the clinician to ask the child’s caregiver about adherence (proxy-report) unless
the child is alone or the caregiver indicates that the child is primarily responsible for taking
his/her own medicines, in which case the child should be asked directly (self-report). For the
7-day quantitative recall, adherence data were collected from responses to the question, “Dur-
ing the last 7 days, how many doses of his/her antiretroviral medicines did the patient take?”
with potential response options of: “none,” “few,” “half,” “most,” and “all.” Good adherence
was defined as reporting that “all” doses were taken. This adherence measure was used at the
AMPATH and MTCT-plus sites. For the 7-day categorical recall of any missed pills, the care-
giver or patient was asked “Has the patient missed any of his/her pills during the last 7 days?”
and the potential responses were only “yes” or “no”. This measure was used by the FACES
sites, and good adherence was equivalent to a “no” response. Adherence was measured
through a clinician pill assessment for the Tanzanian MoHCDGEC sites, where clinicians
asked to see the medication remaining when a child presented for a return visit, did a visual
check of the medication, and then recorded whether the amount of remaining medicine indi-
cated good adherence (defined in their protocol as pills remaining suggesting two or fewer
missed doses over the past month) or poor adherence (pills remaining suggesting three or
more missed doses over the past month.) The clinician pill assessment did not quantify how
Pediatric ART adherence in East Africa
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many pills are remaining, as would be usual for a standard “pill count.” These three different
types of ART adherence measures were collapsed into a binary measure of “good” versus
“poor” ART adherence per visit for all sites to create a summary outcome assessing the adher-
ence across these sites.
Statistical analyses
We used descriptive statistics to describe this cohort of East African children at enrolment into
care and at ART initiation. Adherence (“good” vs. “poor”) was described for various time peri-
ods after ART initiation, by site and by a number of factors including demographics, patient
volume at the site (expressed as the number of patients within a site having recorded visits at
each time point) and treatment course (expressed as weeks from ART initiation). Program
attrition was defined as not having a visit for any reason for more than 90 days since database
closure. The database did not distinguish between the end of observation due to mortality or
treatment disengagement. Measures of time from ART initiation were censored at the time of
attrition, and estimates of the probability of remaining on follow-up were produced using the
Kaplan-Meier method. Conversely, times from ART start were censored at database closure or
reaching one’s 13th birthday, and program attrition was considered the event of interest when
estimates of program retention (defined as one-minus the probability of attrition) were calcu-
lated. The effect of adherence on program attrition was assessed via a Cox model with multiple
adherence evaluations per patient considered as time-dependent covariates.
We fit a hierarchical, three-level logistic regression model, with observations nested within
patients and patients within sites (sites were each of the 26 clinics belonging to the 4 East
Africa IeDEA pediatric care programs participating in this study). We report the relative vari-
ability associated with the level “site” and the level “patient” to quantify the relative proportion
of variability attributed to each factor. A few other patient-level and site-level factors were also
used in the exploratory data analysis. With regard to patient-level factors we concentrated on
age and gender as well as the duration of exposure to antiretroviral therapy. We also examined
the effect of patient volume (number of patients per site at the same time point) as a proxy of
program size, maturity but also burden on human and non-human resources. Statistical analy-
ses were performed using R version 3.4.2 (2017-09-28) (the R Foundation for Statistical
Computing).
Results
Characteristics of eediatric HIV care in East Africa
The East Africa IeDEA cohort included 3,304 HIV-infected children who had been started on
ART at the care systems in Kenya, Uganda, and Tanzania (Table 1). Of the total cohort, the
majority (79.1%) were followed at AMPATH sites in western Kenya. The median age at initia-
tion of ART was 5.5 years (inter-quartile range [IQR] 3.0–8.5 years; Table 1). Just over half of
the children (52.0%) were male. Data on orphan status were only collected for children fol-
lowed at the AMPATH sites. Of the 1,962 children with orphan status known, 55.5% had at
least one parent dead at initiation of ART. At their last visit, the children had been receiving
ART for a median of 91.7 weeks (IQR 47.1–91.7 weeks). Program attrition (loss to follow-up
or death) was 15.8% at one year post-ART initiation (95% CI: 14.5%-17.1%) and 24.3% (95%
CI: 22.5%-26.0%) at two years. In a Cox analysis with good adherence considered as a time-
dependent covariate (i.e., an analysis involving multiple observations per patient), the average
(over all observations) impact of perfect adherence on the time until program attrition was to
slightly reduce the hazard by almost 25% (hazard ratio 0.77, 95% CI 0.53–1.11). However, this
reduction was not statistically significant (p-value 0.160).
Pediatric ART adherence in East Africa
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The measures of adherence used by AMPATH, FACES, MTCT-Plus and the Tanzania
MoHCDGEC programs, along with patient characteristics within each program, are listed in
Table 2. Duration of observation after ART initiation varied greatly within program, with
MTCT-Plus patients being observed the longest (median duration of observation 174 weeks,
inter-quartile range–IQR– 112.1–230.9), while FACES patients were observed for the shortest
duration (median 28.4 weeks, IQR 11.4–56.0 weeks).
Overall, the rates of pediatric adherence among the East Africa sites remained stable over
time, at an average above 90% (range 93.6%-98.4%) throughout all years of follow-up, with a
slight upward trend (Fig 1, black line). The average rates of “good” adherence by six-month
period, after ART initiation, by site and overall are described in Fig 2. The sites in Tanzania,
which used the clinician pill assessment for adherence measurement, had the highest reported
levels of adherence. The overall trend was dominated by AMPATH (the largest care program).
In the hierarchical model, with observations nested within patients and patients within
sites, the variance in reported adherence associated with the site (0.28) was about a third of
the variance associated with individual patients (0.71). (Table 3). Longer time on ART was
Table 1. Characteristics of East African HIV-infected children on antiretroviral therapy (N = 3,165).
Population Characteristics N (%)
Age at ART Initiation
< = 1 year 171 (5.2%)
1–3.0 years 669 (20.2%)
3.0–5.0 years 666 (20.2%)
5.0–7.0 years 587 (17.8%)
7.0–9.0 years 507 (15.3%)
9.0–11.0 years 385 (11.7%)
11.0–13.0 years 290 (8.8%)
Median Age (years) at ART Initiation 5.5 (IQR 3.0–8.5 years)
Gender
Male 1717 (52.0%)
Female 1587 (48.0%)
Orphan Status at ART Initiation (AMPATH only) N = 1,962
At Least 1 Parent Dead 1089 (55.5%)
Both Parents Alive 873 (44.5%)
Tuberculosis at ART Initiation
On Anti-TB Treatment 578 (18.3%)
Not on Anti-TB Treatment 2587 (81.7%)
Median Weeks on ART (95% CI) 91.7 (IQR 88.0–95.1)
https://doi.org/10.1371/journal.pone.0191848.t001
Table 2. Measures of adherence, patient characteristics and duration of follow-up by program in East Africa.
HIV Care & Treatment Program
AMPATH FACES MTCT-Plus TZ MoHCDGEC
N 2613 190 268 233
Adherence Measure Used At Site 7 day 7 day, any missed 7 day 1 month pill count
Median Age at ART Initiation (IQR) 5.6 (3.2–8.5) 5.2 (2.5–8.8) 2.5 (0.9–5.9) 7.1 (4.0–10.1)
Median weeks on ART (95% CI) 90.7 (48.0–126.1) 28.4 (11.4–56.0) 174 (112.1–230.9) 92 (70–110)
Male children (%) 1372 (52.5%) 98 (51.6%) 135 (50.4%) 112 (48.1%)
https://doi.org/10.1371/journal.pone.0191848.t002
Pediatric ART adherence in East Africa
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associated with slightly higher adherence (aOR of the log-transformed week on ART 1.10, 95%
Confidence Interval [1.005–1.015]; p-value <0.001). (Table 3) There was no difference in
adherence depending on the gender of the child or the age at the start of ART. Reported adher-
ence was higher within the programs that saw a higher volume of pediatric patients (Table 3).
Sub-analysis by orphan status
Orphan status was collected only at the start of therapy and only at AMPATH. Consequently,
analyses assessing the impact of orphan status on ART adherence were limited to sites within
this program. Results of the multi-level logistic-regression model applied in this analysis (with
observations nested within AMPATH clinic sites) are shown in Table 4. Orphan status is asso-
ciated with significantly lower odds of good adherence (aOR: 0.78, 95% Confidence Interval
[0.64–0.95]). The impact of the remaining factors considered was consistent as described
above for the complete data analysis.
Discussion
The combined data from pediatric HIV care programs across East Africa suggest that the
majority of HIV-infected children in these settings have good ART adherence on clinical
assessments over a fairly long follow-up period (Fig 2). This level of adherence is similar to
adherence reported over varying time periods within smaller cohorts of patients from East
Africa [50–52] and elsewhere in sub-Saharan Africa.[29, 33] Our analyses of a larger cohort,
with comparisons between sites and evaluation of adherence over time, indicates good ART
adherence while suggesting some critical targets for measuring, supporting and improving
adherence.
Fig 1. Time trend of mean adherence by site (colored loess curves) and overall trend (thick black line).
https://doi.org/10.1371/journal.pone.0191848.g001
Pediatric ART adherence in East Africa
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While ART adherence among East African children was high overall, certain groups may
be prone to non-adherence. Better adherence among younger children suggests that adherence
may become worse as children grow older, highlighting the potential challenges of maintaining
good ART adherence during adolescence.[53] However, this study include predominately
younger children, with only a weak suggestion of diminishing adherence with age. Following
adherence closely as perinatally-infected pediatric cohorts age into adolescence is a key prior-
ity. These data did highlight that the sites with larger patient volumes had more reports of
good pediatric adherence. This finding related to high-volume sites merits closer examination.
Fig 2. Log odds ratio of adherence and 95% confidence interval by site. Sites to the right of 0, are more likely than average to have
good adherence, while sites to the left of 0 are less likely than average to have good adherence.
https://doi.org/10.1371/journal.pone.0191848.g002
Table 3. Multivariate hierarchical model of the odds of good adherence with observations nested within patients
and patients within clinical sites.
Effect of . . . OR 95% CI p-value
Weeks on ART 1.100 1.052–1.150 <0.001
Gender: Male 0.943 0.835–1.065 0.344
Age at ART Start (per year) 0.986 0.968–1.004 0.118
Volume of Patients (in 500-Patient Increments) 00.852 0.803–0.903 <0.001
 Log-transformed
https://doi.org/10.1371/journal.pone.0191848.t003
Pediatric ART adherence in East Africa
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It may be that these sites coping with large patient volumes do not actually have better adher-
ence, but are, in fact, not detecting poor adherence. A site with over-burdened clinicians and
support staff may not have the time or resources to thoroughly assess adherence with individ-
ual families. On the other hand, high-volume sites may be more experienced in detecting and
managing families’ struggles with pediatric adherence, resulting in true improvements in
adherence. The larger, referral centers also often provide care for a sicker population of chil-
dren, creating a form of referral bias, and it is possible that they pay closer attention to adher-
ence for these sicker children at risk of treatment failure. These data do not allow conclusions
to be drawn on this issue.
These analysis provide a unique opportunity to assess the variability in adherence that
could be attributed to site-level differences, in comparison with the individual patient-level
factors typically evaluated. The variance in reported adherence associated with the site was
almost one third as high as the variance associated the individual patients, even after all site-
level factors were accounted for. This observation points that there are significant program-
level factors not accounted for in these data, but also underscore the fact that, in addition to
varying patient characteristics, program-level characteristics are critical in maintaining or
improving adherence. The odds of good adherence increased exponentially with increasing
volume of patients, for example. Addressing pediatric adherence not just within the context of
a given child and caregiver, but as a pervasive clinical program issue appears to be a key strat-
egy for maintaining our gains in the treatment of HIV-infected children over the long-term.
These analyses reveal some important issues related to adherence measurement. The sites
that used pill counts reported much higher estimates of adherence, suggesting that the pill
counts may not have accurately captured instances of non-adherence as higher adherence esti-
mates are typically considered less accurate.[54] These findings may seem surprising since, in
many reports, pill counts have been considered more accurate than recall measures [35, 39, 40,
55, 56]. However, the pill counts described across the East Africa clinical sites in this analysis
were unlike the pill counts used in research settings. In this study, using data from routine clin-
ical care, the actual number of pills dispensed at each visit and any pills remaining at the next
visit were not recorded. Thus, even though the adherence measurement was called a “pill
count”, there were at best only visual checks of the number of pills remaining, which in turn
may have reduced the validity of these measures. Moreover, the sites did not use a specific
method for weighing or estimating the volume of liquid medications, which can alter the accu-
racy of a “pill count” for all of the pediatric patients on liquid formulations. Pill counts were
not directly compared with self-reports or proxy-reports in the sites taking part in this study,
so no comparison can be made as to the pill count validity compared to other measures. Fur-
thermore, the settings using recall measures did not employ any other comparative measures
of adherence, such as pill counts or electronic dose monitoring. Although proxy-reports or
self-reports are the most widely used method of adherence assessment, these reports also tend
Table 4. Sub-analysis assessing the effect of orphan status on ART adherence (AMPATH sites only). Multivariate
hierarchical model with observations nested within patients and patients within AMPATH clinics.
Effect of . . . OR 95% CI p-Value
Weeks on ART 1.190 1.100 1.287 <0.001
Gender: Male 1.120 0.941 1.334 0.200
Age at ART Start (per year) 0.995 0.967 1.024 0.718
Volume of Patients (in 500-Patient Increments) 1.256 1.026 1.538 0.027
Orphaned at initiation of ART 0.919 0.864 0.976 0.012
 Log-transformed
https://doi.org/10.1371/journal.pone.0191848.t004
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to overestimate adherence [35, 37, 38, 40, 42, 43, 54]. No attempt was made to compare the lev-
els of adherence as measured by the three methods because no patient was evaluated with
more than one method. Thus, the method and the site effects were confounded (i.e., any differ-
ences in the levels of adherence could not be reasonably disentangled from the effect that the
sites had on adherence). Reliable, validated measures of ART adherence for children are
urgently needed. The impact of orphanhood on adherence could only be assessed within the
AMPATH program in Kenya, as this was the only program collecting data on the orphan sta-
tus of children. The sub-analyses of this large sub-population of children suggested that
orphanhood is another factor that may be associated wth reduced adherence levels. Given the
critical role of the caregiver in administering medicines to children and in supervising medica-
tion-taking as children age, in combination with the potential economic and social upheaval
that come with the death of a child’s parent or parents, this is not a surprising finding. The
potential impact of orphanhood on children’s adherence points to the need to find strategies
to support this vulnerable population, as well as to ensure measurement of orphan status for
children across sub-Saharan Africa. A final limitation concerns trend toward increasing rates
of good adherence over time. It is possible that, since adherence measures are taken only from
patients returning to clinic, overall adherence may be overestimated as we begin to sample
from the smaller group of patients that is retained in care over time. In the Cox analysis we
performed to assess the possible relationship of imperfect adherence with the hazard of pro-
gram attrition, however, we did not observe a strong association between lower adherence and
higher hazard of loss to program or mortality.
In addition to limitations with respect to measuring adherence, this study has several further
limitations that require consideration. We did not evaluate the relationship of clinical outcomes
such as World Health Organization (WHO) or Centers of Disease Control (CDC) staging, CD4
counts or percentages to the self-report or proxy-reports of adherence. The clinical outcomes for
children cared for within these sites were difficult to assess with accuracy from the available data.
Viral load measurements were not available at these sites during the time of this study. While
CD4 counts and clinical staging should have been collected or performed for most of the enrolled
children, there were a paucity of data for these outcomes from many of the sites. Because of the
gaps in the CD4 results in the clinical data, we chose to report adherence alone across the broad
range of children, rather than to restrict the analyses to only those with complete CD4 data
which would have severely limited our study population (and potentially have biased our results).
The limitation of lacking CD4 comparisons is somewhat allayed by findings in other studies
where reported adherence was not consistently associated with CD4 counts.[26, 57] The clinical
staging data, while contained in these clinical data, are less useful for comparisons with adher-
ence because patients always remain at the highest level of clinical staging that they have reached
regardless of response to therapy. Good adherence, even if it results in an improved clinical pic-
ture, would thus fail to move a patient to a lower or less severe clinical stage.
Our data were limited to those variables available within the common dataset across the
East Africa IeDEA sites. Viral loads were not available, nor were some other variables of poten-
tial importance, such as caregivers’ HIV status, orphan status for all children, and over time, or
orphan care setting. Our study may also have underestimated the extent of ART non-adher-
ence because adherence was based on in-clinic assessments and thus potentially compounded
by clinic non-adherence or social desirability biases. While patients may have some extra med-
ication supplies and should report non-adherence from missed visits during their subsequent
visits, clinic-based ART assessments likely underestimate ART non-adherence. In addition,
the nature of the observational cohort precludes us from making causal inferences.
Despite these limitations, this study has critical advantages that add to the current literature
on pediatric ART adherence. The study involves a large cohort from an entire world region,
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across multiple programs, caring for children and following them for a number of years. The
children in the analysis span a large spectrum of ages, and their general characteristics suggest
that they are representative of a typical population of HIV-infected children in East Africa if
not throughout sub-Saharan Africa. The representativeness of our population is also buoyed
by the fact that we have captured data from both large and small care systems, while maintain-
ing this wide regional representation. Consequently, these data allow for both care systems
and policy makers to consider the challenges to pediatric ART adherence as we attempt to
maintain the survival of an entire generation, from infancy and into adulthood living with
HIV.
Conclusions
Effective disease management for children with HIV depends on sustaining high rates of
adherence. Although ART adherence appears to be very good among children in East Africa,
HIV care systems in resource-limited settings must continue to measure, sustain, and improve
ART adherence. Reliable, valid, affordable measurement strategies that can be employed for
routine adherence measurement are urgently needed.
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